Your session is about to expire
← Back to Search
ABP 938 for Chorioretinal Vascular Disease
Study Summary
This trial studies the accuracy of eye injections with a new drug, ABP 938, compared to an existing drug, aflibercept.
- Chorioretinal Vascular Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there an upper age limit for potential participants in this research?
"As per the eligibility requirements for this trial, the age range accepted is 18 to 99."
What safety precautions are necessary when administering ABP 938 to patients?
"We rate ABP 938's safety at a 3 on the scale of 1-3 due to its Phase 3 status and evidence both for efficacy and multiple rounds of data proving its security."
Are there currently any vacancies in this experiment for volunteers?
"Per clinicaltrials.gov, the trial that was initially posted on 1/23/2023 is currently recruiting participants. This information has been recently updated as of 2/10/2023."
What is the current tally of facilities conducting this clinical trial?
"There are 4 clinical trial sites that have begun recruiting patients, such as the Bellaire Retina Center in Texas, San Antonio's Retina Centre and The Woodlands' Retinal Consultants of Texas."
How many participants are currently enrolled in this research initiative?
"Affirmative. According to the clinicaltrials.gov portal, this medical trial is searching for 48 participants across 4 sites and was initially posted on January 23rd 2023 with a later update occurring on February 10th of that same year."
What are the eligibility requirements for participation in this trial?
"The study requires 48 individuals who have chorioretinal vascular disease and are between 18-99 years of age. The key criteria for applicants include signing an approved informed consent form, being male or female over the age of eighteen, and having neovascular age-related macular degeneration, diabetic macular edema, macular edema due to retinal vein occlusion or diabetic retinopathy in one eye (with treatment not necessary)."
Share this study with friends
Copy Link
Messenger